[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fa39ii2oGc0NvHoAtpLThSmp6GxheVvhNzrpR8fy6D1s":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":48,"rows":55},"Intermountain Health Care, Inc.",[4],118,false,20,7,1654759,4,94,[14,17,20,22,24,26,28,30],{"name":15,"count":16},"Sepsis",6,{"name":18,"count":19},"Atrial Fibrillation",5,{"name":21,"count":19},"Septic Shock",{"name":23,"count":19},"Coronary Artery Disease",{"name":25,"count":19},"Deep Vein Thrombosis",{"name":27,"count":19},"Heart Failure",{"name":29,"count":11},"Carbon Monoxide Poisoning",{"name":31,"count":11},"Cardiovascular Disease",[33,38,43],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT03439267","Effectiveness of a Proactive Cardiovascular Primary Prevention Strategy, With or Without the Use of Coronary Calcium Screening, in Preventing Future Major Adverse Cardiac Events","2026-04-06","Coronary Artery Calcium Screening and Statin Treatment",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT06217562","Vasopressin for Septic Shock Pragmatic Trial","2026-07","Vasopressin",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT07376889","Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia","2029-01","Antibiotic Monotherapy",[49,50,51,52,53,54],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[56,81,99,121,143,169,187,215,233,258,287,311,338,364,382,409,447,469,496,514,541,559,582,609,632,668,693,711,734,761,779,807,825],{"intervention":47,"totalTrials":57,"cells":58},1,{"EARLY_PHASE1":59,"PHASE1":62,"PHASE2":64,"PHASE3":66,"PHASE4":68,"NA":79},{"trials":60,"activeCount":61},[],0,{"trials":63,"activeCount":61},[],{"trials":65,"activeCount":61},[],{"trials":67,"activeCount":61},[],{"trials":69,"activeCount":57,"soonestReadout":46},[70],{"nctId":44,"briefTitle":45,"status":71,"phases":72,"primaryCompletion":46,"completion":46,"start":73,"enrollment":74,"conditions":75,"interventions":77},"NOT_YET_RECRUITING",[53],"2026-02-01",2096,[76],"Staphylococcus Aureus Bacteremia",[47,47,78,78],"Combination Antibiotic Therapy",{"trials":80,"activeCount":61},[],{"intervention":78,"totalTrials":57,"cells":82},{"EARLY_PHASE1":83,"PHASE1":85,"PHASE2":87,"PHASE3":89,"PHASE4":91,"NA":97},{"trials":84,"activeCount":61},[],{"trials":86,"activeCount":61},[],{"trials":88,"activeCount":61},[],{"trials":90,"activeCount":61},[],{"trials":92,"activeCount":57,"soonestReadout":46},[93],{"nctId":44,"briefTitle":45,"status":71,"phases":94,"primaryCompletion":46,"completion":46,"start":73,"enrollment":74,"conditions":95,"interventions":96},[53],[76],[47,47,78,78],{"trials":98,"activeCount":61},[],{"intervention":42,"totalTrials":57,"cells":100},{"EARLY_PHASE1":101,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":109,"NA":119},{"trials":102,"activeCount":61},[],{"trials":104,"activeCount":61},[],{"trials":106,"activeCount":61},[],{"trials":108,"activeCount":61},[],{"trials":110,"activeCount":57,"soonestReadout":41},[111],{"nctId":39,"briefTitle":40,"status":112,"phases":113,"primaryCompletion":41,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":118},"ACTIVE_NOT_RECRUITING",[53],"2027-12","2024-02-01",2050,[21],[42],{"trials":120,"activeCount":61},[],{"intervention":37,"totalTrials":57,"cells":122},{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":131,"NA":133},{"trials":124,"activeCount":61},[],{"trials":126,"activeCount":61},[],{"trials":128,"activeCount":61},[],{"trials":130,"activeCount":61},[],{"trials":132,"activeCount":61},[],{"trials":134,"activeCount":57,"soonestReadout":36},[135],{"nctId":34,"briefTitle":35,"status":112,"phases":136,"primaryCompletion":36,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":142},[54],"2027-04-06","2018-03-26",5765,[141],"Cardiovascular Primary Prevention Strategy",[37],{"intervention":144,"totalTrials":57,"cells":145},"aspirin",{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":154,"NA":167},{"trials":147,"activeCount":61},[],{"trials":149,"activeCount":61},[],{"trials":151,"activeCount":61},[],{"trials":153,"activeCount":61},[],{"trials":155,"activeCount":61},[156],{"nctId":157,"briefTitle":158,"status":159,"phases":160,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":165},"NCT00343876","Clopidogrel and Aspirin Together: The Effect on C-Reactive Protein Trial","COMPLETED",[53],"2006-11","2005-07",100,[23],[144,166],"clopidogrel",{"trials":168,"activeCount":61},[],{"intervention":166,"totalTrials":57,"cells":170},{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":177,"PHASE4":179,"NA":185},{"trials":172,"activeCount":61},[],{"trials":174,"activeCount":61},[],{"trials":176,"activeCount":61},[],{"trials":178,"activeCount":61},[],{"trials":180,"activeCount":61},[181],{"nctId":157,"briefTitle":158,"status":159,"phases":182,"completion":161,"start":162,"enrollment":163,"conditions":183,"interventions":184},[53],[23],[144,166],{"trials":186,"activeCount":61},[],{"intervention":188,"totalTrials":57,"cells":189},"Dabigatran Etexilate",{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":196,"PHASE4":198,"NA":213},{"trials":191,"activeCount":61},[],{"trials":193,"activeCount":61},[],{"trials":195,"activeCount":61},[],{"trials":197,"activeCount":61},[],{"trials":199,"activeCount":61},[200],{"nctId":201,"briefTitle":202,"status":159,"phases":203,"primaryCompletion":204,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":211},"NCT03061006","Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation",[53],"2021-03-15","2017-03-30",101,[208,209,210],"Dementia","Cognition Disorders","Cerebral Ischemic Events",[188,212],"Warfarin",{"trials":214,"activeCount":61},[],{"intervention":212,"totalTrials":57,"cells":216},{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":225,"NA":231},{"trials":218,"activeCount":61},[],{"trials":220,"activeCount":61},[],{"trials":222,"activeCount":61},[],{"trials":224,"activeCount":61},[],{"trials":226,"activeCount":61},[227],{"nctId":201,"briefTitle":202,"status":159,"phases":228,"primaryCompletion":204,"completion":204,"start":205,"enrollment":206,"conditions":229,"interventions":230},[53],[208,209,210],[188,212],{"trials":232,"activeCount":61},[],{"intervention":234,"totalTrials":57,"cells":235},"valsartan",{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":244,"NA":256},{"trials":237,"activeCount":61},[],{"trials":239,"activeCount":61},[],{"trials":241,"activeCount":61},[],{"trials":243,"activeCount":61},[],{"trials":245,"activeCount":61},[246],{"nctId":247,"briefTitle":248,"status":249,"phases":250,"completion":251,"start":252,"enrollment":253,"conditions":254,"interventions":255},"NCT00343499","The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)","TERMINATED",[53],"2007-07","2004-11",200,[18],[234],{"trials":257,"activeCount":61},[],{"intervention":259,"totalTrials":57,"cells":260},"Vitamin D3",{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":267,"PHASE4":269,"NA":285},{"trials":262,"activeCount":61},[],{"trials":264,"activeCount":61},[],{"trials":266,"activeCount":61},[],{"trials":268,"activeCount":61},[],{"trials":270,"activeCount":61},[271],{"nctId":272,"briefTitle":273,"status":159,"phases":274,"primaryCompletion":275,"completion":276,"start":277,"enrollment":278,"conditions":279,"interventions":284},"NCT02996721","A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients",[53],"2025-03-30","2025-09-04","2017-04-03",634,[280,281,282,283],"Death","Myocardial Infarction","Cerebral Vascular Accident","Heart Failure Hospitalization",[259],{"trials":286,"activeCount":61},[],{"intervention":288,"totalTrials":57,"cells":289},"AVANDAMET",{"EARLY_PHASE1":290,"PHASE1":292,"PHASE2":294,"PHASE3":296,"PHASE4":298,"NA":309},{"trials":291,"activeCount":61},[],{"trials":293,"activeCount":61},[],{"trials":295,"activeCount":61},[],{"trials":297,"activeCount":61},[],{"trials":299,"activeCount":61},[300],{"nctId":301,"briefTitle":302,"status":249,"phases":303,"primaryCompletion":304,"completion":305,"start":306,"enrollment":253,"conditions":307,"interventions":308},"NCT00343395","Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable Coronary Syndromes (Romance) Pilot Study",[53],"2007-11","2008-01","2006-06",[23],[288],{"trials":310,"activeCount":61},[],{"intervention":312,"totalTrials":57,"cells":313},"Dosing of enoxaparin for VTE prophylaxis",{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":320,"PHASE4":322,"NA":336},{"trials":315,"activeCount":61},[],{"trials":317,"activeCount":61},[],{"trials":319,"activeCount":61},[],{"trials":321,"activeCount":61},[],{"trials":323,"activeCount":61},[324],{"nctId":325,"briefTitle":326,"status":327,"phases":328,"primaryCompletion":329,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":335},"NCT01916707","Weight Based Enoxaparin in Trauma Patients","UNKNOWN",[53],"2017-06","2017-12","2013-07",1200,[334],"Venous Thromboembolism",[312],{"trials":337,"activeCount":61},[],{"intervention":339,"totalTrials":57,"cells":340},"Hyperbaric Oxygen (HBO2) - 3 sessions",{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":347,"PHASE4":349,"NA":362},{"trials":342,"activeCount":61},[],{"trials":344,"activeCount":61},[],{"trials":346,"activeCount":61},[],{"trials":348,"activeCount":61},[],{"trials":350,"activeCount":61},[351],{"nctId":352,"briefTitle":353,"status":159,"phases":354,"primaryCompletion":355,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":360},"NCT00465855","One vs. Three Hyperbaric Oxygen Treatments for Acute Carbon Monoxide Poisoning",[53],"2016-09-10","2017-01-28","2007-06-03",75,[29],[339,361],"Hyperbaric Oxygen (HBO2) - 1 session",{"trials":363,"activeCount":61},[],{"intervention":361,"totalTrials":57,"cells":365},{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":374,"NA":380},{"trials":367,"activeCount":61},[],{"trials":369,"activeCount":61},[],{"trials":371,"activeCount":61},[],{"trials":373,"activeCount":61},[],{"trials":375,"activeCount":61},[376],{"nctId":352,"briefTitle":353,"status":159,"phases":377,"primaryCompletion":355,"completion":356,"start":357,"enrollment":358,"conditions":378,"interventions":379},[53],[29],[339,361],{"trials":381,"activeCount":61},[],{"intervention":383,"totalTrials":57,"cells":384},"apixaban",{"EARLY_PHASE1":385,"PHASE1":387,"PHASE2":389,"PHASE3":391,"PHASE4":393,"NA":407},{"trials":386,"activeCount":61},[],{"trials":388,"activeCount":61},[],{"trials":390,"activeCount":61},[],{"trials":392,"activeCount":61},[],{"trials":394,"activeCount":61},[395],{"nctId":396,"briefTitle":397,"status":249,"phases":398,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":402,"interventions":406},"NCT02945280","Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis",[53],"2021-11-11","2017-02-22",52,[403,404,405,334,25],"Deep Venous Thrombosis","Upper Extremity Deep Venous Thrombosis","Thrombus",[383],{"trials":408,"activeCount":61},[],{"intervention":410,"totalTrials":411,"cells":412},"Hydroxychloroquine",2,{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":431,"PHASE4":443,"NA":445},{"trials":414,"activeCount":61},[],{"trials":416,"activeCount":61},[],{"trials":418,"activeCount":61},[419],{"nctId":420,"briefTitle":421,"status":159,"phases":422,"primaryCompletion":423,"completion":424,"start":425,"enrollment":426,"conditions":427,"interventions":429},"NCT04329832","Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19",[51],"2020-07-01","2021-01-01","2020-03-30",85,[428],"COVID-19",[410,430],"Azithromycin",{"trials":432,"activeCount":61},[433],{"nctId":434,"briefTitle":435,"status":327,"phases":436,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":442},"NCT04334382","Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19",[52],"2020-12-31","2021-12-31","2020-04-02",1550,[428],[410,430],{"trials":444,"activeCount":61},[],{"trials":446,"activeCount":61},[],{"intervention":430,"totalTrials":411,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":459,"PHASE4":465,"NA":467},{"trials":450,"activeCount":61},[],{"trials":452,"activeCount":61},[],{"trials":454,"activeCount":61},[455],{"nctId":420,"briefTitle":421,"status":159,"phases":456,"primaryCompletion":423,"completion":424,"start":425,"enrollment":426,"conditions":457,"interventions":458},[51],[428],[410,430],{"trials":460,"activeCount":61},[461],{"nctId":434,"briefTitle":435,"status":327,"phases":462,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":463,"interventions":464},[52],[428],[410,430],{"trials":466,"activeCount":61},[],{"trials":468,"activeCount":61},[],{"intervention":470,"totalTrials":57,"cells":471},"Outpatient Dinoprostone 10mg",{"EARLY_PHASE1":472,"PHASE1":474,"PHASE2":476,"PHASE3":478,"PHASE4":492,"NA":494},{"trials":473,"activeCount":61},[],{"trials":475,"activeCount":61},[],{"trials":477,"activeCount":61},[],{"trials":479,"activeCount":61},[480],{"nctId":481,"briefTitle":482,"status":249,"phases":483,"primaryCompletion":484,"completion":485,"start":486,"enrollment":487,"conditions":488,"interventions":490},"NCT03806231","A Trial of Cervidil for Outpatient Pre-induction of Cervical Ripening",[52],"2019-12-05","2020-04-11","2019-08-07",8,[489],"Induction of Labor Affected Fetus \u002F Newborn",[470,491],"Inpatient Dinoprostone 10 mg",{"trials":493,"activeCount":61},[],{"trials":495,"activeCount":61},[],{"intervention":491,"totalTrials":57,"cells":497},{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":510,"NA":512},{"trials":499,"activeCount":61},[],{"trials":501,"activeCount":61},[],{"trials":503,"activeCount":61},[],{"trials":505,"activeCount":61},[506],{"nctId":481,"briefTitle":482,"status":249,"phases":507,"primaryCompletion":484,"completion":485,"start":486,"enrollment":487,"conditions":508,"interventions":509},[52],[489],[470,491],{"trials":511,"activeCount":61},[],{"trials":513,"activeCount":61},[],{"intervention":515,"totalTrials":57,"cells":516},"IWPC adapted genotype-guided dosing algorithm for warfarin",{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":523,"PHASE4":537,"NA":539},{"trials":518,"activeCount":61},[],{"trials":520,"activeCount":61},[],{"trials":522,"activeCount":61},[],{"trials":524,"activeCount":61},[525],{"nctId":526,"briefTitle":527,"status":159,"phases":528,"primaryCompletion":529,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":535},"NCT00927862","Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin",[51,52],"2010-12","2011-06","2008-08",2415,[534],"Thromboembolism",[515,536],"Modified IWPC genetic-guided warfarin dosing algorithm",{"trials":538,"activeCount":61},[],{"trials":540,"activeCount":61},[],{"intervention":536,"totalTrials":57,"cells":542},{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":549,"PHASE4":555,"NA":557},{"trials":544,"activeCount":61},[],{"trials":546,"activeCount":61},[],{"trials":548,"activeCount":61},[],{"trials":550,"activeCount":61},[551],{"nctId":526,"briefTitle":527,"status":159,"phases":552,"primaryCompletion":529,"completion":530,"start":531,"enrollment":532,"conditions":553,"interventions":554},[51,52],[534],[515,536],{"trials":556,"activeCount":61},[],{"trials":558,"activeCount":61},[],{"intervention":560,"totalTrials":57,"cells":561},"Esmolol",{"EARLY_PHASE1":562,"PHASE1":564,"PHASE2":566,"PHASE3":576,"PHASE4":578,"NA":580},{"trials":563,"activeCount":61},[],{"trials":565,"activeCount":61},[],{"trials":567,"activeCount":61},[568],{"nctId":569,"briefTitle":570,"status":159,"phases":571,"primaryCompletion":572,"completion":572,"start":573,"enrollment":9,"conditions":574,"interventions":575},"NCT02841241","Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia",[51],"2017-03","2016-04",[21],[560],{"trials":577,"activeCount":61},[],{"trials":579,"activeCount":61},[],{"trials":581,"activeCount":61},[],{"intervention":583,"totalTrials":57,"cells":584},"SAFEstart",{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":603,"PHASE4":605,"NA":607},{"trials":586,"activeCount":61},[],{"trials":588,"activeCount":61},[],{"trials":590,"activeCount":61},[591],{"nctId":592,"briefTitle":593,"status":159,"phases":594,"completion":595,"start":162,"enrollment":8,"conditions":596,"interventions":602},"NCT00331201","SAFEstart Feeding Intolerance Study Phase II",[51],"2006-04",[597,598,599,600,601],"Feeding Intolerance","Abdominal Distention","Gastric Residual","Emesis and Diarrhea","Blood in Stool",[583],{"trials":604,"activeCount":61},[],{"trials":606,"activeCount":61},[],{"trials":608,"activeCount":61},[],{"intervention":610,"totalTrials":57,"cells":611},"Ranolazine",{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":626,"PHASE4":628,"NA":630},{"trials":613,"activeCount":61},[],{"trials":615,"activeCount":61},[],{"trials":617,"activeCount":61},[618],{"nctId":619,"briefTitle":620,"status":249,"phases":621,"primaryCompletion":622,"completion":622,"start":623,"enrollment":487,"conditions":624,"interventions":625},"NCT01887353","The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure",[51],"2014-02","2013-06",[18,27],[610],{"trials":627,"activeCount":61},[],{"trials":629,"activeCount":61},[],{"trials":631,"activeCount":61},[],{"intervention":633,"totalTrials":411,"cells":634},"Hyperbaric Oxygen",{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":649,"PHASE3":651,"PHASE4":653,"NA":655},{"trials":636,"activeCount":61},[],{"trials":638,"activeCount":61},[639],{"nctId":640,"briefTitle":641,"status":327,"phases":642,"primaryCompletion":643,"completion":643,"start":644,"enrollment":645,"conditions":646,"interventions":648},"NCT02563678","Hyperbaric Oxygen, Neutrophil-oxidative Burst, and Cytokines",[50],"2023-12","2015-04",40,[647],"Infection",[633],{"trials":650,"activeCount":61},[],{"trials":652,"activeCount":61},[],{"trials":654,"activeCount":61},[],{"trials":656,"activeCount":61},[657],{"nctId":658,"briefTitle":659,"status":159,"phases":660,"primaryCompletion":661,"completion":661,"start":662,"enrollment":663,"conditions":664,"interventions":666},"NCT01430325","Test of Chamber Pressure to Divers and Chamber Attendants",[54],"2011-10","2011-07",42,[665],"Traumatic Brain Injury",[633,667],"Sham Chamber Session",{"intervention":669,"totalTrials":57,"cells":670},"Metformin",{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":679,"NA":681},{"trials":672,"activeCount":61},[],{"trials":674,"activeCount":61},[],{"trials":676,"activeCount":61},[],{"trials":678,"activeCount":61},[],{"trials":680,"activeCount":61},[],{"trials":682,"activeCount":61},[683],{"nctId":684,"briefTitle":685,"status":686,"phases":687,"primaryCompletion":688,"completion":688,"start":689,"enrollment":61,"conditions":690,"interventions":692},"NCT01171456","Early Intervention for Gestational Diabetes","WITHDRAWN",[54],"2010-07","2010-04",[691],"Gestational Diabetes Mellitus",[669],{"intervention":667,"totalTrials":57,"cells":694},{"EARLY_PHASE1":695,"PHASE1":697,"PHASE2":699,"PHASE3":701,"PHASE4":703,"NA":705},{"trials":696,"activeCount":61},[],{"trials":698,"activeCount":61},[],{"trials":700,"activeCount":61},[],{"trials":702,"activeCount":61},[],{"trials":704,"activeCount":61},[],{"trials":706,"activeCount":61},[707],{"nctId":658,"briefTitle":659,"status":159,"phases":708,"primaryCompletion":661,"completion":661,"start":662,"enrollment":663,"conditions":709,"interventions":710},[54],[665],[633,667],{"intervention":712,"totalTrials":57,"cells":713},"Standard of care or genotyping dosing of warfarin dosing",{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":720,"PHASE4":722,"NA":724},{"trials":715,"activeCount":61},[],{"trials":717,"activeCount":61},[],{"trials":719,"activeCount":61},[],{"trials":721,"activeCount":61},[],{"trials":723,"activeCount":61},[],{"trials":725,"activeCount":61},[726],{"nctId":727,"briefTitle":728,"status":159,"phases":729,"completion":304,"start":730,"enrollment":253,"conditions":731,"interventions":733},"NCT00334464","A Pharmacogenetic Study of Warfarin Dosing, \"The COUMA-GEN Study\"",[54],"2006-02",[18,25,732],"Pulmonary Embolism",[712],{"intervention":735,"totalTrials":57,"cells":736},"Alvimopam",{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":743,"PHASE4":745,"NA":747},{"trials":738,"activeCount":61},[],{"trials":740,"activeCount":61},[],{"trials":742,"activeCount":61},[],{"trials":744,"activeCount":61},[],{"trials":746,"activeCount":61},[],{"trials":748,"activeCount":61},[749],{"nctId":750,"briefTitle":751,"status":159,"phases":752,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":757,"interventions":759},"NCT01143259","Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use",[54],"2012-06","2012-08","2010-05",274,[758],"Ileus",[735,760],"300 mg Polyethylene",{"intervention":760,"totalTrials":57,"cells":762},{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":769,"PHASE4":771,"NA":773},{"trials":764,"activeCount":61},[],{"trials":766,"activeCount":61},[],{"trials":768,"activeCount":61},[],{"trials":770,"activeCount":61},[],{"trials":772,"activeCount":61},[],{"trials":774,"activeCount":61},[775],{"nctId":750,"briefTitle":751,"status":159,"phases":776,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":777,"interventions":778},[54],[758],[735,760],{"intervention":780,"totalTrials":57,"cells":781},"fenofibrate 160 mg and placebo",{"EARLY_PHASE1":782,"PHASE1":784,"PHASE2":786,"PHASE3":788,"PHASE4":790,"NA":792},{"trials":783,"activeCount":61},[],{"trials":785,"activeCount":61},[],{"trials":787,"activeCount":61},[],{"trials":789,"activeCount":61},[],{"trials":791,"activeCount":61},[],{"trials":793,"activeCount":61},[794],{"nctId":795,"briefTitle":796,"status":159,"phases":797,"completion":798,"start":799,"enrollment":800,"conditions":801,"interventions":804},"NCT00309712","Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study",[54],"2006-09","2002-08",300,[802,803],"Type II Diabetes Mellitus","Mixed Dyslipidemia",[780,805,806],"simvastatin 20 mg and placebo","fenofibrate 160 mg and simvastatin 20 mg",{"intervention":805,"totalTrials":57,"cells":808},{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":815,"PHASE4":817,"NA":819},{"trials":810,"activeCount":61},[],{"trials":812,"activeCount":61},[],{"trials":814,"activeCount":61},[],{"trials":816,"activeCount":61},[],{"trials":818,"activeCount":61},[],{"trials":820,"activeCount":61},[821],{"nctId":795,"briefTitle":796,"status":159,"phases":822,"completion":798,"start":799,"enrollment":800,"conditions":823,"interventions":824},[54],[802,803],[780,805,806],{"intervention":806,"totalTrials":57,"cells":826},{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":831,"PHASE3":833,"PHASE4":835,"NA":837},{"trials":828,"activeCount":61},[],{"trials":830,"activeCount":61},[],{"trials":832,"activeCount":61},[],{"trials":834,"activeCount":61},[],{"trials":836,"activeCount":61},[],{"trials":838,"activeCount":61},[839],{"nctId":795,"briefTitle":796,"status":159,"phases":840,"completion":798,"start":799,"enrollment":800,"conditions":841,"interventions":842},[54],[802,803],[780,805,806]]